L3VLUP
ProSign in

AMGN · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AMGNGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AMGN
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterAMGNGILD
Q3 202016 holders, $16.3bn25 holders, $14.2bn
Q4 202019 holders, $14.0bn27 holders, $13.4bn
Q1 202116 holders, $14.5bn24 holders, $14.5bn
Q2 202123 holders, $13.8bn18 holders, $14.9bn
Q3 202124 holders, $11.6bn20 holders, $16.4bn
Q4 202121 holders, $10.4bn20 holders, $16.8bn
Q1 202223 holders, $9.9bn28 holders, $13.2bn
Q2 202228 holders, $9.7bn26 holders, $13.6bn
Q3 202221 holders, $7.9bn24 holders, $13.3bn
Q4 202224 holders, $9.3bn32 holders, $21.1bn
Q1 202322 holders, $8.4bn27 holders, $21.8bn
Q2 202326 holders, $7.4bn24 holders, $20.7bn
Q3 202326 holders, $8.7bn24 holders, $20.0bn
Q4 202324 holders, $8.4bn22 holders, $21.5bn
Q1 202425 holders, $6.7bn30 holders, $20.3bn
Q2 202420 holders, $8.0bn28 holders, $18.5bn
Q3 202421 holders, $8.8bn29 holders, $24.2bn
Q4 202420 holders, $8.2bn28 holders, $25.9bn
Q1 202525 holders, $12.0bn33 holders, $32.0bn
Q2 202520 holders, $10.2bn27 holders, $30.9bn
Q3 202517 holders, $10.4bn23 holders, $29.4bn
Q4 202519 holders, $18.0bn25 holders, $34.3bn
Q1 202615 holders, $21.4bn25 holders, $38.5bn
Q2 202623 holders, $24.9bn26 holders, $34.2bn
AMGN

Amgen Inc

Holders
17
Reported value
$10.4bn
Buyers
8
Sellers
9

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
23
Reported value
$29.4bn
Buyers
9
Sellers
14

Breadth -5 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2025

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AMGN (5)

ARK Investment Management LLC, ExodusPoint Capital Management LP, Tudor Investment Corp, Two Sigma Advisers LP, Verition Fund Management LLC

Only GILD (11)

AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Citadel Advisors LLC, Holocene Advisors LP, Marshall Wace LLP, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →